dioscin has been researched along with epirubicin in 1 studies
| Studies (dioscin) | Trials (dioscin) | Recent Studies (post-2010) (dioscin) | Studies (epirubicin) | Trials (epirubicin) | Recent Studies (post-2010) (epirubicin) |
|---|---|---|---|---|---|
| 250 | 0 | 200 | 5,453 | 1,838 | 1,570 |
| Protein | Taxonomy | dioscin (IC50) | epirubicin (IC50) |
|---|---|---|---|
| Genome polyprotein | 0.75 | ||
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 5.181 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, FY; Fu, M; He, SY; Jing, M; Ju, RJ; Kong, L; Li, XT; Liu, JJ; Liu, XZ; Yao, XM; Zhang, L | 1 |
1 other study(ies) available for dioscin and epirubicin
| Article | Year |
|---|---|
RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Diosgenin; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Rats; Xenograft Model Antitumor Assays | 2020 |